In August 2026, Moderna and Merck jointly announced that their AI-customized personalized mRNA cancer vaccine, intismeran (V940/mRNA-4157), achieved a major breakthrough in the Phase III clinical trial INTerpath-001, becoming the world's first personalized cancer vaccine proven effective in a Phase III trial. The trial enrolled 1,137 high-risk (Stage IIB-IV) melanoma patients, and the results showed that, compared to using Keytruda (pembrolizumab) alone, the combination of intismeran and Keytruda significantly prolonged patients' recurrence-free survival (RFS) and distant metastasis-free survival (DMFS), with a good safety profile. Following the announcement, Moderna's stock price surged by over 110% in a single day. This achievement marks a new era in tumor immunotherapy, bringing fresh hope to cancer patients.